Volumetry based biomarker speed of growth

• Verfasst von: Wennmann, Markus [VerfasserIn]
• Verfasst von: Hielscher, Thomas [VerfasserIn]
• Verfasst von: Kauczor, Hans-Ulrich [VerfasserIn]
• Verfasst von: Merz, Maximilian [VerfasserIn]
• Titel: Volumetry based biomarker speed of growth
• Titelzusatz: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients
• Verf.angabe: Markus Wennmann, Laurent Kintzelé, Marie Piraud, Bjoern H. Menze, Thomas Hielscher, Johannes Hofmanninger, Barbara Wagner, Hans-Ulrich Kauczor, Maximilian Merz, Jens Hillengass, Georg Langs and Marc-André Weber
• E-Jahr: 2018
• Jahr: May 18, 2018
• Umfang: 11 S.
• Fussnoten: Gesehen am 12.03.2020
• Titel Quelle: Enthalten in: OncoTarget
• Ort Quelle: [S.l.] : Impact Journals LLC, 2010
• Jahr Quelle: 2018
• Band/Heft Quelle: 9(2018), 38, Seite 25254-25264
• ISSN Quelle: 1949-2553
• DOI: doi:10.18632/oncotarget.25402
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 169235535X

Abstract

The purpose of this study was to improve risk stratification of smoldering multiple myeloma patients, introducing new 3D-volumetry based imaging biomarkers derived from whole-body MRI. Two-hundred twenty whole-body MRIs from 63 patients with smoldering multiple myeloma were retrospectively analyzed and all focal lesions >5mm were manually segmented for volume quantification. The imaging biomarkers total tumor volume, speed of growth (development of the total tumor volume over time), number of focal lesions, development of the number of focal lesions over time and the recent imaging biomarker ‘>1 focal lesion’ of the International Myeloma Working Group were compared, taking 2-year progression rate, sensitivity and false positive rate into account. Speed of growth, using a cutoff of 114mm3/month, was able to isolate a high-risk group with a 2-year progression rate of 82.5%. Additionally, it showed by far the highest sensitivity in this study and in comparison to other biomarkers in the literature, detecting 63.2% of patients who progress within 2 years. Furthermore, its false positive rate (8.7%) was much lower compared to the recent imaging biomarker ‘>1 focal lesion’ of the International Myeloma Working Group. Therefore, speed of growth is the preferable imaging biomarker for risk stratification of smoldering multiple myeloma patients.